Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page’s footer/version indicator was updated from **Revision: v3.5.2** to **Revision: v3.5.3**, reflecting a background site update rather than a change to the clinical trial information.
    Difference
    0.0%
    Check dated 2026-04-24T17:09:28.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Deleted Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-17T14:08:40.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    IQVIA Pty Ltd was added as a collaborator and Iqvia Pty Ltd was removed, correcting the sponsor/collaborator listing.
    Difference
    0.0%
    Check dated 2026-04-10T09:13:58.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Website revision updated from v3.4.3 to v3.5.0; no core study details appear to be affected.
    Difference
    0.0%
    Check dated 2026-03-19T23:48:42.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    Revision: v3.4.3 has been added. No visible changes to the study details or page layout were observed.
    Difference
    0.0%
    Check dated 2026-03-12T20:14:02.000Z thumbnail image
  6. Check
    76 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page. The previous items, including a government-funding operating-status notice and Revision: v3.4.1, were removed.
    Difference
    0.4%
    Check dated 2026-02-11T23:58:06.000Z thumbnail image

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.